Active, not recruitingPhase 2NCT04589650
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Studying PIK3CA-related overgrowth syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Alpelisib(drug)
- Enrollment
- 206 target
- Eligibility
- 100 years · All sexes
- Timeline
- 2021 – 2031
Study locations (30)
- UCSF Birthmarks and Vascular Center, San Francisco, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Washington Univ School Of Medicine, St Louis, Missouri, United States
- Fink Childrens Ambulatory Care Ctr, New York, New York, United States
- UNC Chapel Hill, Chapel Hill, North Carolina, United States
- Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States
- Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
- CHOP Abramson Pediatric Resch Ctr, Philadelphia, Pennsylvania, United States
- Unv of TX Southwestern Medical Center, Dallas, Texas, United States
- Baylor College Of Medicine, Houston, Texas, United States
- Childrens Hospital and Regional Medical Center, Seattle, Washington, United States
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Bordeaux, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04589650 on ClinicalTrials.govOther trials for PIK3CA-related overgrowth syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06997588EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Novartis Pharmaceuticals
- RECRUITINGNANCT06840015Use of Airpod Pros as Assistive TechnologyThe University of Texas at Dallas
- RECRUITINGPHASE2NCT06789913A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA MutationRelay Therapeutics, Inc.
- RECRUITINGNCT06956248Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)National Cancer Centre, Singapore
- RECRUITINGNCT06364579Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE1, PHASE2NCT06975618Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)Haihe Biopharma Co., Ltd.
- RECRUITINGNCT05898932Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesNorthwestern University
- ACTIVE NOT RECRUITINGNCT05705947PROs Following Low-dose Irradiation for OsteoarthritisUniversity of North Carolina, Chapel Hill